908 Devices announced the appointment of Kola Otitoju as Chief Business & Strategy Officer, a newly created executive role aimed at accelerating the company’s next phase of growth. In this position, Otitoju will lead product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as the company expands across public health, safety, and defense technology markets.
Otitoju brings more than 25 years of executive leadership experience spanning strategy, business development, and P&L management across the medical technology, life sciences, and industrial sectors. He most recently served as Senior Vice President of Strategy & Business Development at Repligen Corporation, where he led global corporate strategy and executed more than 15 M&A transactions and strategic partnerships over six years. His efforts supported approximately 20% compound annual growth, helping scale the company to more than $700 million in revenue.
Earlier in his career, Otitoju held senior roles at Candela Medical, Baxter International, and GE Healthcare, where he was Managing Director and Head of Business Development. He also spent eight years in investment banking at Credit Suisse and Bank of America Securities, advising on M&A transactions across healthcare, industrials, and technology sectors. He holds an MBA from Harvard Business School, a master’s degree in electrical engineering from Cornell University, and a bachelor’s degree in information systems from Imperial College London.
Alongside the appointment, 908 Devices announced an inducement equity grant for Otitoju under Nasdaq Listing Rule 5635(c)(4). On April 21, 2026, the company granted 110,193 restricted stock units and stock options to purchase 146,789 shares of common stock under its 2026 Inducement Plan. The RSUs will vest equally over three years through May 1, 2029, contingent on continued service. The stock options carry an exercise price of $7.26 per share, matching the company’s closing stock price on the grant date, and will vest over three years, with one-third vesting after the first year and the remainder vesting monthly thereafter.
908 Devices develops handheld chemical analysis tools designed for point-of-need applications, enabling rapid identification of unknown substances across critical use cases such as drug detection, toxic exposure, and global security threats. The company integrates analytical technologies, software automation, and machine learning to deliver actionable insights in real time.
KEY QUOTE:
“We are thrilled to welcome Kola to 908 Devices as we build on the momentum of our 2.0 transformation and enter our next phase of growth. His exceptional track record in driving both organic and inorganic growth makes him the ideal leader to accelerate our strategic initiatives and deliver long-term shareholder value. M&A and industry partnerships have already been successful and integral to our strategy, and we intend to lean in further. Kola’s appointment reinforces this commitment and positions us to execute at an even higher level.”
Kevin J. Knopp, CEO And Co-founder, 908 Devices
